Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the ...

Researchers determine the clinical and demographic risk factors of paradoxical eczema as well as the overall incidence and biologic-class-specific risk factors and incidence of paradoxical eczema in ...

Interleukin-6 (IL-6) is a pleiotropic cytokine that may play a role in the regulation of various aspects of the immune response, inflammation, hematopoiesis, and bone metabolism. IL-6 acts by binding ...

Sanofi SA has synthesized interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic ...

A new analysis of novel biologic therapies for patients with psoriatic disease included 32,098 biologic-naïve patients with psoriasis or psoriatic arthritis. Participants were placed in 1 of 4 cohorts ...

Nuphase Therapeutics (Shanghai) Co. Ltd. has disclosed compounds acting as interleukin-17A/A homodimer and IL-17A/F heterodimer inhibitors reported to be useful for the treatment of cancer, autoimmune ...

(MENAFN- GlobeNewsWire - Nasdaq) The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease ...

A case-time-control study found no association between the initiation of interleukin 17 (IL-17) receptor A inhibitors and major adverse cardiovascular events (MACEs). Researchers conducted a case-time ...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors" report has been added to ResearchAndMarkets.com's offering. This competitive ...